Loading patent…
OwnerDavid Goldstein, Xian-Jun Qu +2inventors
InventorsDavid Goldstein, Xian-Jun Qu, Pamela Russell, Jia-Lin Yang
Estimating the term…
The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and IFNα combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and IFNα combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as TARCEVA®).
A pharmaceutical composition comprising an EGFR kinase inhibitor and IFNα in a pharmaceutically acceptable carrier.
A method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and IFNα.
A method for the treatment of cancer, comprising administering to a subject in need of such treatment a first amount of an EGFR kinase inhibitor, or a pharmaceutically acceptable salt thereof, and a second amount of IFNα wherein at least one of the amounts is administered as a sub-therapeutic amount.
Dependencies are inferred from the claim text.